We are live on ! Find out more
EP

Eversept Partners Portfolio holdings

AUM $1.93B Turnover 41.06%
1-Year Est. Return 160.8%
This Fund
S&P 500
This Quarter Est. Return
+29.23%
1 Year Est. Return
+160.8%
3 Year Est. Return
+321.09%
5 Year Est. Return
+420.29%
10 Year Est. Return
–
AUM
$852M
AUM Growth
+$402M
Cap. Flow
+$256M
Cap. Flow %
30.02%
Top 10 Hldgs %
54.49%
Holding
73
New
24
Increased
20
Reduced
15
Closed
11
Avg Time Held Equity + Options
0.8 years
Top 10 Avg Time Held Equity + Options
0.4 years
Top 20 Avg Time Held Equity + Options
0.9 years
Avg Time Held Equity only
0.9 years
Top 10 Avg Time Held Equity only
0.4 years
Top 20 Avg Time Held Equity only
0.9 years

Top Buys

Rank Stock Value
1
ALXN
Alexion Pharmaceuticals
ALXN
+$48.3M
2
AZN icon
AstraZeneca
AZN
+$41.9M
3
GSK icon
GSK
GSK
+$32.4M
4
UTHR icon
United Therapeutics
UTHR
+$28.6M
5
AMRN icon
Amarin Corp
AMRN
+$25.5M

Top Sells

Rank Stock Value
1
BHVN icon
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
+$18.5M
2
OSUR icon
OraSure Technologies
OSUR
+$11.4M
3
HSKA
Heska Corp
HSKA
+$10.3M
4
LAB icon
Standard BioTools
LAB
+$9.68M
5
DCPH icon
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
+$9.26M

Sector Composition

Rank Sector Weight
1 Healthcare 97.63%
2 Miscellaneous 2.33%
3 Financials 0.05%
4 Communication Services 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
BHVN icon
26
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$8.89M 1.04%
103,764
-217,817
-68% -$18.5M
2020 Q1
3 quarters
MGLN
27
DELISTED
Magellan Health Services, Inc.
MGLN
$8.67M 1.02%
+104,700
New +$8.28M
2020 Q4
0 quarters
RAD
28
DELISTED
Rite Aid Corporation
RAD
$8.42M 0.99%
+532,004
New +$6.84M
2020 Q4
0 quarters
AUPH icon
29
Aurinia Pharmaceuticals
AUPH
$2.22B
$8.36M 0.98%
604,368
+168,373
+39% +$2.45M
2020 Q2
2 quarters
MCRB icon
30
Seres Therapeutics
MCRB
$25.3M
$8.18M 0.96%
+16,702
New +$9.78M
2020 Q4
0 quarters
QDEL icon
31
QuidelOrtho
QDEL
$939M
$7.29M 0.86%
40,583
+31,240
+334% +$6.94M
2020 Q3
1 quarter
AMRN icon
32
CALL
Amarin Corp
AMRN
$244M
$6.29M 0.74%
64,270
+1,065
+2% +$103K
2019 Q3
5 quarters
AFMD icon
33
DELISTED
Affimed
AFMD
$5.61M 0.66%
96,471
-28,075
-23% -$1.32M
2018 Q1
11 quarters
AMRX icon
34
Amneal Pharmaceuticals
AMRX
$6.68B
$5.38M 0.63%
1,178,153
-1,478,055
-56% -$6.55M
2020 Q2
2 quarters
OXFD
35
DELISTED
Oxford Immunotec Global PLC Ordinary Shares
OXFD
$5.37M 0.63%
307,742
+14,465
+5% +$203K
2019 Q3
5 quarters
ALT icon
36
Altimmune
ALT
$445M
$4.29M 0.5%
+380,000
New +$4.48M
2020 Q4
0 quarters
BCRX icon
37
BioCryst Pharmaceuticals
BCRX
$2B
$3.66M 0.43%
491,852
-651,359
-57% -$3.36M
2017 Q4
12 quarters
FPRX
38
DELISTED
Five Prime Therapeutics, Inc.
FPRX
$3.56M 0.42%
+209,155
New +$2.62M
2020 Q4
0 quarters
SNY icon
39
Sanofi
SNY
$96.8B
$3.31M 0.39%
68,138
+18,360
+37% +$906K
2017 Q4
12 quarters
HCA icon
40
HCA Healthcare
HCA
$101B
$2.76M 0.32%
16,754
-35,646
-68% -$5.21M
2020 Q1
3 quarters
PRTA icon
41
Prothena Corp
PRTA
$431M
$2.44M 0.29%
203,328
+6,300
+3% +$74.5K
2020 Q2
2 quarters
CARM icon
42
DELISTED
Carisma Therapeutics
CARM
$2.11M 0.25%
77,991
– –
2019 Q4
4 quarters
ANAB icon
43
AnaptysBio
ANAB
$1.43B
$1.9M 0.22%
+88,334
New +$2.15M
2020 Q4
0 quarters
SRDX icon
44
DELISTED
Surmodics
SRDX
$1.8M 0.21%
+41,299
New +$1.63M
2020 Q4
0 quarters
ONCT icon
45
DELISTED
Oncternal Therapeutics, Inc. Common Stock
ONCT
$1.69M 0.2%
+17,205
New +$1.09M
2020 Q4
0 quarters
OTIC
46
DELISTED
Otonomy, Inc.
OTIC
$1.64M 0.19%
253,283
-159,217
-39% -$723K
2019 Q1
7 quarters
AUTL icon
47
Autolus Therapeutics
AUTL
$439M
$1.39M 0.16%
+154,981
New +$1.65M
2020 Q4
0 quarters
CNCE
48
DELISTED
Concert Pharmaceuticals, Inc.
CNCE
$1.31M 0.15%
103,829
– –
2020 Q2
2 quarters
ATXS icon
49
DELISTED
Astria Therapeutics
ATXS
$1.12M 0.13%
+87,007
New +$1.55M
2020 Q4
0 quarters
XGN icon
50
Exagen
XGN
$188M
$1.08M 0.13%
+81,603
New +$1.15M
2020 Q4
0 quarters
1
2
3

Similar funds

SWM
Segment Wealth Management Houston, Texas $1.93B AUM 29.24% 1-Year Est. Return
RIA
Regal Investment Advisors Kentwood, Michigan $1.92B AUM 23.13% 1-Year Est. Return
SI
Standard Investments New York $1.93B AUM 6.23% 1-Year Est. Return
SG
Sourcerock Group Denver, Colorado $1.92B AUM 45.54% 1-Year Est. Return
DCP
Distillate Capital Partners Chicago, Illinois $1.92B AUM 5.31% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return
FWP
FAS Wealth Partners Leawood, Kansas $1.92B AUM 26.86% 1-Year Est. Return

Eversept Partners's Q4 2020 Portfolio in Review

As of Q4 2020, Eversept Partners held 73 positions worth $852M, up 89% from $450M the previous quarter. Its ten largest holdings account for 54% of the portfolio.

Eversept Partners deployed $256M of net new capital in Q4 2020, opening 24 new positions and adding to 20 existing holdings. Its largest new stake was Alexion Pharmaceuticals: 376,200 shares worth $58.8M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 97% a quarter earlier, followed by Miscellaneous and Financials.

On the sell side, the largest reduction was Biohaven Pharmaceutical Holding Company Ltd., an estimated $18.5M trimmed.

  • Eversept Partners's largest Q4 2020 buy was Alexion Pharmaceuticals: 376,200 shares worth $58.8M.
  • Eversept Partners added most to AstraZeneca in Q4 2020, an estimated $41.9M increase.
  • Eversept Partners's biggest Q4 2020 reduction was Biohaven Pharmaceutical Holding Company Ltd., cutting an estimated $18.5M.
  • Eversept Partners fully exited OraSure Technologies in Q4 2020, selling an estimated $11.4M.
  • Eversept Partners's ten largest holdings make up 54% of its $852M portfolio in Q4 2020.
  • Eversept Partners opened 24 new positions and closed 11 in Q4 2020.
  • Eversept Partners's portfolio value rose 89% quarter-over-quarter to $852M.

Based on Eversept Partners's 13F filing for Q4 2020, filed 16 Feb 2021.